{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:23Z","timestamp":1785473963977,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate real-world effectiveness and safety of omadacycline for elderly community-acquired pneumonia (CAP) versus tigecycline, moxifloxacin, and cefoperazone-sulbactam after inverse probability of treatment weighting (IPTW).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study enrolled non-ICU hospitalized elderly CAP patients. Missing covariates were handled by multiple imputation, and IPTW balanced groups. Primary outcome was pragmatic clinical response (improvement in at least one of laboratory markers, chest imaging, or clinical symptoms), with a sensitivity analysis requiring all three. Secondary outcomes included hospital stay, antibiotic duration, microbiological clearance, and adverse events. Subgroup analyses used age &amp;lt; 75 vs \u2265 75 years and CURB-65 &amp;lt; 2 vs \u2265 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,208 patients were included: 177 in the omadacycline group, 124 in the tigecycline group, 666 in the moxifloxacin group, and 241 in the cefoperazone-sulbactam group. After IPTW adjustment, omadacycline showed a pragmatic clinical response comparable to tigecycline, higher than moxifloxacin, but lower than cefoperazone-sulbactam. Omadacycline was associated with shorter hospital stay than tigecycline and cefoperazone-sulbactam, but longer than moxifloxacin; antibiotic duration was comparable to tigecycline, shorter than cefoperazone-sulbactam, but longer than moxifloxacin. Microbiological clearance was lower with omadacycline in the evaluable subset, whereas recorded adverse events were fewer but limited by rare-event sparsity. Exploratory subgroup analyses suggested that cefoperazone-sulbactam had a higher response than omadacycline in patients aged &amp;lt;75 years or with CURB-65 &amp;lt;2. Subgroup analyses suggested heterogeneous associations by age and disease severity and should be interpreted as exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world analysis of elderly patients with CAP after IPTW adjustment, omadacycline showed a pragmatic clinical response comparable to tigecycline, higher than moxifloxacin, but lower than cefoperazone-sulbactam. Omadacycline was associated with shorter hospital stay than tigecycline and cefoperazone-sulbactam, but longer hospital stay than moxifloxacin. Antibiotic duration was comparable to tigecycline, shorter than cefoperazone-sulbactam, but longer than moxifloxacin. Given the broad pragmatic endpoint, high baseline response rate, sensitivity to endpoint definition and missing-data handling, incomplete microbiological follow-up, and residual confounding inherent to retrospective data, these findings should be interpreted as exploratory and require prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1875598","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:27Z","timestamp":1785471927000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinran","family":"Xie","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Jilin University","place":["Changchun, China"]},{"name":"Department of Pharmacy of Lequn Branch, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of Lequn Branch, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of Lequn Branch, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Song","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Jilin University","place":["Changchun, China"]},{"name":"Department of Pharmacy of Lequn Branch, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40266-016-0423-9","article-title":"How antibiotics should be prescribed to hospitalized elderly patients with community-acquired pneumonia","volume":"34","author":"Arnold","year":"2017","journal-title":"Drugs Aging"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17","article-title":"Pharmacokinetics and safety of omadacycline in subjects with impaired renal function","volume":"62","author":"Berg","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"190126","DOI":"10.1183\/16000617.0126-2019","article-title":"Community-acquired pneumonia in critically ill very old patients: a growing problem","volume":"29","author":"Cill\u00f3niz","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmi.2014.09.011","article-title":"The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly","volume":"21","author":"Corsonello","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00134-025-08252-x","article-title":"Severe community-acquired pneumonia: current concepts and controversies","volume":"52","author":"Dequin","year":"2026","journal-title":"Intensive Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/QCO.0000000000001005","article-title":"Epidemiology of community-acquired pneumonia caused by S treptococcus pneumoniae in older adults: a narrative review","volume":"37","author":"Elias","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s12325-020-01248-7","article-title":"Burden of community-acquired pneumonia and unmet clinical needs","volume":"37","author":"Ferreira-Coimbra","year":"2020","journal-title":"Adv. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/aje\/kwx222","article-title":"Measurement error due to patient flow in estimates of intensive care unit length of stay","volume":"186","author":"Harhay","year":"2017","journal-title":"Am. J. Epidemiol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106491","article-title":"Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients","volume":"59","author":"Huang","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1512288","article-title":"Clinical characteristics and risk factors of hospital mortality in elderly patients with community-acquired pneumonia","volume":"12","author":"Li","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101195","article-title":"Potential cost savings associated with targeted substitution of current guideline-concordant inpatient agents with omadacycline for the treatment of adult hospitalized patients with community-acquired bacterial pneumonia at high risk for Clostridioides difficile infections: results of healthcare-decision analytic model from the United States hospital perspective","volume":"10","author":"Lodise","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-026-01726-7","article-title":"Understanding antibiotic prescribing in the inpatient setting: a synthesis of evidence on determinants and interventions","volume":"15","author":"Ma","year":"2026","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2024.111998","article-title":"Challenges of infectious diseases in older adults: from immunosenescence and inflammaging through antibiotic resistance to management strategies","volume":"222","author":"Mancinetti","year":"2024","journal-title":"Mech. Ageing Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2025.02.025","article-title":"Comprehensive management of pneumonia in older patients","volume":"135","author":"Putot","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/resp.12851","article-title":"Age-related risk factors for bacterial aetiology in community-acquired pneumonia","volume":"21","author":"Sahuquillo-Arce","year":"2016","journal-title":"Respirology (Carlton Vic.)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S570","DOI":"10.1093\/infdis\/jiz053","article-title":"Global and regional burden of hospital admissions for pneumonia in older adults: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40266-023-01019-3","article-title":"Safety and tolerability of antimicrobial agents in the older patient","volume":"40","author":"Soraci","year":"2023","journal-title":"Drugs Aging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40268-025-00531-8","article-title":"Omadacycline pharmacokinetics: characteristics, contributing factors, and clinical significance","volume":"25","author":"Sun","year":"2025","journal-title":"Drugs R. D."},{"key":"B24","first-page":"625","article-title":"Community-acquired pneumonia in adults: rapid evidence review","volume":"105","author":"Womack","year":"2022","journal-title":"Am. Fam. Physician"},{"key":"B25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2014.01.017","article-title":"A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone\/sulbactam","volume":"23","author":"Xia","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1627","article-title":"Comparison of efficacy and safety profiles between omadacycline and moxifloxacin in elderly patients with community-acquired pneumonia: a randomized, controlled trial","volume":"15","author":"Yu","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1875598\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:29Z","timestamp":1785471929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1875598\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":24,"alternative-id":["10.3389\/fcimb.2026.1875598"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1875598","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1875598"}}